FUTURE COUNCIL and CAN BOARD MEETINGS

<table>
<thead>
<tr>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 16</td>
<td>January 15-16</td>
</tr>
<tr>
<td>May 16</td>
<td>May 21-22</td>
</tr>
<tr>
<td>September 19</td>
<td>September 24-25</td>
</tr>
<tr>
<td><strong>CAN Board only (by phone)</strong></td>
<td><strong>CAN Board only (by phone)</strong></td>
</tr>
<tr>
<td>December 11</td>
<td>December 12</td>
</tr>
</tbody>
</table>

Agenda – OPEN SESSION

Open Session of the meeting will be webcast. To view, please go to:  [http://videocast.nih.gov/summary.asp?live=13505](http://videocast.nih.gov/summary.asp?live=13505)

8:30 - 8:50 a.m.  CALL TO ORDER, OPEN SESSION

Christopher P. Austin, M.D.  Freda Lewis-Hall, M.D.
Director, NCATS  Chief Medical Officer, Pfizer
Chairperson - Advisory Council  Chairperson - CAN Board

8:50 - 9:00 a.m.  Approval of Minutes of 4th Joint Meeting

Confirmation of Dates for Future NCATS Advisory Council/CAN Review Board Meetings

Danilo A. Tagle, Ph.D., Executive Secretary, NCATS Advisory Council

9:00 - 10:00 a.m.  NCATS DIRECTOR’S REPORT

Christopher P. Austin, M.D., Director, NCATS

Discussion
10:00 - 10:30 a.m.  **BREAK**

10:30 - 11:15 a.m.  **CAN Review Board Report on Other Transactions**
Freda Lewis-Hall M.D., Chief Medical Officer, Pfizer
Discussion

11:15 a.m. - Noon  **Project Opportunity/Need Analyses in Translational Science**
Christopher P. Austin, M.D., Director, NCATS
Discussion

Noon - 1:00 p.m.  **LUNCH**

1:00 - 1:45 p.m.  **Rare Diseases: Then and Now – 30 Years of Advancements**
Stephen Groft, Pharm.D., Director, ORDR, NCATS
Discussion

1:45 - 2:15 p.m.  **Pediatric Study-Researcher Matching**
W. Charles Huskins, M.D., M.Sc., Professor of Pediatrics, Mayo Clinic
Discussion

2:15 - 2:45 p.m.  **REPORT FROM COUNCIL SUBCOMMITTEES**
- Patient engagement
- Partnerships with pharmaceutical and biotechnology companies and venture capital firms
- Medical technologies (devices and diagnostics)
Discussion

2:45 - 3:00 p.m.  **Concept Clearance**
Platform Delivery Technologies for Nucleic Acid Therapeutics
P.J. Brooks, Ph.D., Health Scientist Administrator, ORDR, NCATS
3:00 p.m.  

**ADJOURN, OPEN SESSION**

3:15 - 5:00 p.m.  

**CLOSED SESSION**

This portion of the meeting is closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S. Code and Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2).

**Review of Conflict of Interest, Confidentiality and Council Procedures**

Danilo A. Tagle, Ph.D., Executive Secretary, NCATS Advisory Council

**Council Consideration of Pending Applications**

Danilo A. Tagle, Ph.D., Executive Secretary, NCATS Advisory Council